Ignapan-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Pantoprazole 40 mg, designed to provide effective management of gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and discomfort associated with delayed gastric emptying or gastroparesis. Pantoprazole, a proton pump inhibitor, suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing relief from acid-related disorders including gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcer disease. The synergistic action of Domperidone and Pantoprazole in Ignapan-DSR Capsule addresses both motility dysfunction and acid hypersecretion, making it suitable for patients presenting with combined symptoms. This combination therapy enhances patient compliance by reducing pill burden and optimizing therapeutic outcomes. Ignapan-DSR should be used under medical supervision, with caution advised in patients with known hypersensitivity to either component, cardiac arrhythmias, or significant hepatic impairment. The dosage and duration of therapy should be individualized based on clinical response and tolerability. Common adverse effects may include headache, dry mouth, and gastrointestinal disturbances.